PTO/SB/08A (08-03)

PTO/SB/08A (08-03)
Approved for use through 07/3 1/2006. OMB 0613-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
crossos are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known Application Number 10/602,694 INFORMATION DESCLOSU STATEMENT BY APPLICAN Filing Date June 20, 2003 First Named Inventor Sommadossi et al. Group Art Unit 1614 Examiner Name (use as many sheets as necessary) Unassigned Shect Attorney Docket Number 6 06171.105073 IDX 1006 CON1

						3425635 I
				U.S. PATENT DOCUMENTS		
Examiner Initials *	Cite No. 1			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pgs, Clmns, Lns, Where Relevant Passages/Relevant Figs Appear
(6)	AA	3,480,613	Α	Walton et al.	11-25-1969	
	AB	5,977,061	A	De Clercq	11-02-1999	
	AC	6,340,690	Bl	Bachand et al.	01-22-2002	
	AD	6,348,587	BI	Schinazi et al.	02-2002	
	AE	6,395,716	B1	Gosselin et al. (Novirio / Idenix)	05-28-2002	
	AF	6,444,652	B1	Gosselin et al. (Novirio / Idenix)	09-03-2002	
	AG	6,573,248	B1	Ramasamy et al.	06-03-2003	
·	AH	2002/0019363	A1	Ismaili et al.	02-2002	
	_A1	2002/0055483	A1	Watanabe et al.	05-09-2002	
_	AJ	2002/0147160	Al	Bhat et al.	10-10-2002	
	AK	2003/008841	A1	Devos et al.	01-09-2003	
	AL	2003/028013	Al	Wang et al.	02-06-2003	
	AM	2003/0050229	Al	Sommadossi et al.	03-13-2003	
-1/-	AN	2003/0060400	Al	LaColla et al.	03-27-2003	
	AO	2003/0083307	A1	Devos et al.	05-01-2003	
100	AP	2003/0087873	A1	Stuyver et al.	05-08-2003	

				FOF	REIGN PATENT DOCUMENTS			_
Examiner Initials *	Cite No. 1	Foreign Patent Document Office ³ Number Kind Code ² (if known)		Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD- YYYY	Pages, Calumns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
<u>u</u>	AQ	FR	1,521,076	Α	Merck & Co. Inc.	04-12-1968		1
	AR	FR	1,581,628	Α	Merck & Co. Inc.	09-19-1969		-
	AS	FR	2,662,165	Α	Univ. Paris Curie	11-22-1991		\vdash
	AT	GB	1,163,103	A	Merck & Co. Inc.	09-04-1969		 -
	AU	GB	1,209,654	Α	Merck & Co. Inc.	10-21-1970		┝
	AV	JP	63-215694	A	Yamasa Shoyu Co, Ltd.	09-08-1988		┢
	AW	JP	06-228186	Α	Yamasa Shoyu Co, Ltd.	08-16-1994		-
	_AX	WO	98/16184	A2	ICN Pharmaceuticals	04-23-1998		-
<u> </u>	AY	wo	99/43691	Al	Emory U.; U.Ga.R.F.	02-09-1999		-
Ж	AZ	wo	00/09531	A2	Novirio Pharm. (Idenix)	02-24-2000		-
(W	AAA	wo	01/32153	A2	Biochem Pharma	05-10-2001		-

Examiner Signature	Date Considered	3/31/	05

*EXAMINER: Initial if reference considered, whether or not clistion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with sext communication to applicant.

Burdes More Stuteness: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time part as required to compute in form about the seas to the Chief Information Officer. U. S. Peters and Tradecards Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FUNDAS TO THIS ADDRESS, SEND TO: Assistant Commissione for Peters Washington, DC 20231.

^{**}Ubige or Cultion forigination number.** See stracked Kinds of U.S. Patent Documents. **Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Typenese patent Geometrus, he indicated on the year of the relign at the Emperor must procedule see senial number of the patent document. **Kind of document by the appropriate symbols as indicated on the document code "FIFO" Scandard ST. 10 for Spoths. **Application is a to patent active. The Kind Patent St. 10 for Spoths. **Application is a total-ord.**

	Under the Paperwi	rk Keduction	Act of 1995, no perso	ons are required to respond to a collecti	on of information unless it contains a valid OMB control number.		
Substitu	te for form 1449A/PTO			Complete if Known			
				Application Number	10/602,694		
INF	ORMATION I	DISCLO	OSURE	Filing Date	June 20, 2003		
STA	TEMENT BY	APPLI	CANT	First Named Inventor	Sommadossi et al.		
				Group Art Unit	1614		
	(use as many sheets	as necessar	y)	Examiner Name	Unassigned		
Sheet	2	of	6	Attorney Docket Number 06171.105073 IDX 1006 CON1			

3425635 1 FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Pages, Columns, Lines, Where Relevant xaminer Cite Name of Patentee or Applicant of Office3 Number Kind Code2 Publication of No. 1 T۴ Initials * Cited Document Cited Document Passages or Relevant Figures Appear (if known) MM-DD- YYYY Δ RΔ wo 01/60315 Biochem Pharma 08-23-2001 BB wo 01/68663 Al ICN Pharmaceuticals 09-20-2001 BC WO 01/79246 A2 Pharmasset 10-25-2001 BD WO 01/90121 A2 Novirio Pharm, (Idenix) 11-29-2001 BE WO 01/91737 A2 Novirio Pharm. (Idenix) 06-12-2001 BF wo 01/92282 A2 Novirio Pharm. (Idenix) 06-12-2001 RG wo 01/96353 A2 Novirio Pharm. (Idenix) 12-20-2001 BH wo 02/03997 Al ICN Pharmaceuticals 01-17-2002 BI wo 02/18404 A2 F. Hoffmann-La Roche 03-07-2002 BJ wo 02/32920 A2 Pharmasset 04-25-2002 BK wo 02/48165 A2 Pharmasset 06-20-2002 BL wo 02/057287 A2 Merck & Co. Inc. 07-25-2002 BM wo 02/057425 A2 Merck & Co. Inc. 07-25-2002 BN wo 02/070533 A2 Pharmasset 09-12-2002 BO wo 02/094289 ΑI F. Hoffmann-La Roche 11-28-2002 RP wo 02/100415 A2 F. Hoffmann-La Roche 12-19-2002 wo BO 03/026589 A2 Idenix; CNRS; U. Montp. 04-03-2003 BR wo 03/026675 Αĩ Idenix; CNRS; U. Monto. 04-03-2003 BS wo 03/051899 Al Ribapharm 06-26-2003 BT wo 03/061385 Αı Ribapharm 07-31-2003 BU wo 03/061576 A2 Ribapharm 07-31-2003 BV wo 03/062255 A2 Ribapharm 07-31-2003 BW wo 03/062256 AI Ribapharm 07-31-2003 BX wo 03/062257 ΑI Ribapharm 07-31-2003 RY WO 03/063771 A2 Pharmasset 08-07-2003 BZ wo 03/068162 A2 Pharmasset 08-21-2003 BAA wo 03/072757 A2 Biota Inc. 09-04-2003 BAB WO 03/093290 A2 Genelabs Technologies 11-13-2003 BAC wo 04/002422 A2 Idenix; Univ.D.S.Cagliari 01-08-2004 BAD WO 04/002999 A2 Idenix: Univ.D.S.Cagliari

Examiner	Date	_//	
Signature	Considered	3/31/09	3
		The second liverage in the later in the late	

01-08-2004

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{**}Unique clustion designation number: **See stateched Kinds of U.S. Parent Documents. **Eater Office that issued the document, by the two-letter code (WIPO Standard ST.3). **For parts documents, the indication of the year of the reign of the Emparyr many procede the serial number of the parent document. **Kind document by the appropriate procedure in the company of the company o

Bridge Man Statement: This form is estimated to take 2.9 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the annual of time you are required to complete this farm should be sent to the Chief Information Officer. U. S. Peters and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Astinated Commissions for Parties, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/602,694 INFORMATION DISCLOSURE Filing Date June 20, 2003 First Named Inventor STATEMENT BY APPLICANT Sommadossi et al. Group Art Unit 1614 Examiner Name (use as many sheets as necessary) Unassigned Attorney Docket Number Sheet 3 of 6 06171.105073 IDX 1006 CON1

			635 _. [
Examiner	Cite	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Initials *	No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or courtry where published.	1
	CA	ALTMANN et al, "The synthesis of 1'-methyl carbocyclic thymidine and its effect on nucleic acid	T ⁶
(19)		duplex stability," Synlett, Thieme Verlag, Stuttgart, De, 10:853-855 (1994).	1
	CB BAGINSKI, S. G, et al., "Mechanism of action of a pestivirus antiviral compound," PNAS USA,		-
		97(14):7981-7986 (2000).	
	cc	BEIGELMAN, L.N., et al, "Epimerization during the acetolysis of 3-O-acetyl-5-O-benzoyl-1,2-O-	
		isopropylidene-3-C-methyl-α,D-ribofuranose. Synthesis of 3'-C-methylnucleosides with the β-D-	
		ribo- and α-D-arabino configurations," Carbohydrate Research, 181:77-88 (1988)	
1	CD	BEIGELMAN, L.N., et al, "A general method for synthesis of 3'-C-alkylnucleosides," Nucleic Acids	_
		Symp. Ser., 9:115-118 (1981).	
	CE	BERENGUER, M., et al, "Hepatitis B and C viruses: Molecular identification and targeted antiviral	
		therapies," Proceedings of the Association of American Physicians, 110(2), 98-112 (1998)	
1 1	CF	CARROLL, S.S., et al., "Inhibition of hepatitis C virus RNA replication by 2'-modified pucleoside	
		analogs," The Journal of Biological Chemistry, 278(14):11979-11984 (2003).	
	CG	CZERNECKI, S., et al, "Synthesis of various 3'-branched 2',3'-unsaturated pyrimidine nucleosides as	
		potential anti-HIV agents," J. Org. Chem., 57:7325-7328 (1992).	
1 1	CH	De FRANCESCO, R., et al., "Approaching a new era for hepatitis C virus therapy: Inhibitors of the	
		NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase," Antiviral Research, 58:1-	
		16 (2003).	
1 1	C1	FAIVRE-BUET, V., et al, "Synthesis of 1'-deoxypsicofuranosyl-deoxynucleosides as potential anti-	
-		HIV agents," Nucleosides & Nucleotides, 11(7):1411-1424 (1992)	
- 1 1	CJ	FARKAS, J., et al., "Nucleic acid components and their analogues. XCIV. Synthesis of 6-amino-9-(1-	
		deoxy-β-D-psicofuranosyl)purine", Collect. Czech. Chem. Commun. 32:2663-2667 (1967)	
- 1 - 1	CK	FARKAS, J., et al., "Nucleic acid components and their analogues, LXXIX, Synthesis of methyl 1-	
- 1 1		deoxy-D-psicofuranosides substituted at C(1) with halo atoms or a mercapto group." Collect. Czech.	
\perp		Chem. Commun., 31:1535-1543 (1996).	
- 1	CL	FEDOROV, I.I., et al, "3'-C-Branched 2'-deoxy-5-methyluridines: Synthesis, enzyme inhibition, and	-
-		antiviral properties," J. Med. Chem., 35(24):4567-4575 (1992).	
	CM	FRANCHETTI, P., et al., "2'-C-Methyl analogues of selective adenosine recentor agonists: synthesis	_
	i	and binding studies," J. Med. Chem., 41(10):1708-1715 (1998).	
V	CN	GROUILLER, A., et al., "Novel p-toluenesulfonylation and thionocarbonylation of unprotected	_
		thymine nucleosides," Synlett, 1993, 221-222 (March 1993).	
(617)	co	HARAGUCHI, K., et al., "Preparation and reactions of 2'- and 3'- vinyl bromides of uracil	
u		nucleosides: Versatile synthons for anti-HIV agents," Tetrahedron Letters, 32(28):3391-3394 (1991).	- 1

Examiner 4	Date	0/2.	1.0
Signature	Considered	7/51	/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Bordon How Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete in form about be sent to the Chief Information Officer. U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Precess, Washington, DC 20231.

^{**}Unique citation designation number: **See structed Kinds of U.S. Patent Documents. **Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). **For Apparets patent documents, the indication of the year of the reign of the Emperer must provide the serial number of the patent document. **I kind of document by the appropriate symbols is indicated to the document outs of the Standard ST.3 in the serial number of the patent document. **I kind of document by the appropriate symbols is indicated to the document outs' in the Standard ST.3 in the patent document. **I kind of document by the appropriate symbols is indicated to the document outs' in the Standard ST.3 in the serial number of the patent document. **I kind of document by the appropriate symbols is indicated to the document outs' in the Standard ST.3 in the serial number of the patent document. **I kind of document by the appropriate symbols is indicated to the document outs' in the serial number of the patent document. **I kind of document by the appropriate symbols is indicated to the document outs' in the serial number of the patent document. **I kind of document by the appropriate symbols is indicated to the document outs' in the serial number of the patent document. **I kind of document by the appropriate symbols is indicated in the serial number of the patent document. **I kind of document by the appropriate symbols is indicated in the serial number of the patent document. **I kind of document by the appropriate symbols is indicated in the serial number of the patent document. **I kind of the serial number of the patent document. **I kind of the serial number of the patent document. **I kind of the serial number of the patent document. **I kind of the number of the patent document. **I kind of the number of the patent document. **I kind of the number of the patent document. **I kind of the number of the patent document. **I kind of the number of the patent document. **I kind of the number of the patent document. **I kind of

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

INFORMATION DISCLOSUDE Filing Date 10/602,694											
INI	June 20, 2003										
ST,	ATEN	1ENT BY	APPLI	ICANT	First Named Inventor	Sommadossi et al.					
					Group Art Unit	1614					
(use as many sheets as necessary) Examiner Name Unassigned											
Sheet		4 of 6 Attorney Docket Number 06171.105073 IDX 1006 COI									
	3425635 1										
		ОТН	ER PRIC	OR ART - NON	PATENT LITERATUR	E DOCUMENTS					
Examiner Initials *	Cite No. 1	journal, serial,	symposium	, catalog, etc.), date, p	age(s), volume-issue number(s).	ppropriate), title of the item (book, magazine, publisher, city and/or courtry where published.	T ⁶				
(150)	DA	HARAGUC	HARAGUCHI, K., et al., "Stereoselective synthesis of 1'-C-branched uracil nucleosides from								
100		uridine," Nu	cleosides	& Nucleotides, 1	4(3-5):417-420 (1995).						
1	DB	HARRY-O'	HARRY-O'KURU, R.E., et al., "A short, flexible route toward 2'-C-branched ribonucleosides", J.Org. Chem., 62:1754-1759 (1997). (Scheme 11).								
-+-	DC	LIABBY O	7., 02:1/3	4-1/39 (1997). (8	scheme II).						
		Nucleosides	& Nuclea	c.E., et al., 2 -C- otides, 16(7-9):14	57-1460 (1997). I"Rog	esign, synthesis, and conformation," ers" in #2; correct name in #7]	. 1				
	DD	HATTORI,	H., et al,	"Nucleosides and	nucleotides, 175, Struct	ural requirements of the sugar moiety	-				
	i	for the antitu	ımor activ	vities of new nucl	eoside antimetabolites, 1-	(3-C-ethynyl-b-D-ribo-					
•		pentofurano:	syl)cytosi	ne and -uracil," J.	Med. Chem., 41:2892-29	002 (1998).					
1	DE	HREBABEO	CKY, H.,	et al., "Nucleic ac	cid components and their	analogues. CXLIX. Synthesis of					
	1	pyrimidine r	ucleoside	es derived from 1-	deoxy-D-psicose," Collec	ct. Czech. Chem. Commun., 37:2059-					
			2065 (1972).								
	DF	HREBABEC	HREBABECKY, H., et al. "Synthesis of 7- and 9β-D-psicofuranosylguanine and their 1'-deoxy								
-	-	derivatives,"	derivatives," Collect. Czech. Chem. Commun., 39:2115-2123 (1974).								
	DG	IINO, T., et	(O, T., et al., "Nucleosides and nucleotides. 139. Stereoselective synthesis of (2'S)-2'-C-alkyl-2'- oxyuridines," Nucleosides and Nucleotides, 15(1-3):169-181 (1996).								
-+-	DH	ucoxyuridine	s, Nucle	osiaes and Nucle	otides, 15(1-3):169-181 (1996).					
- 1	υп	110H, Y., el	DH, Y., et al, "Divergent and stereocontrolled approach to the synthesis of uracil nucleosides								

Substitute for form 1449A/PTO

DI

DI.

DM

Signature

14(1&2):185-194 (1995).

>	DN	MATSUDA, A., et al., "Radical deoxygenation of tet-alcohols in 2'-branched-chain sugar pyrimidine nucleosides: Synthesis and antileukemic activity of 2'-deoxy-2'(S)-methylcytidine," Chem. Pharm. Bull., 35(9):3967-3970 (1987).	
	DO	MATSUDA, A., et al., "Alkyl addition reaction of pyrimidine 2'-ketonucleosides: Synthesis of 2'- branched-chain sugar pyrimidine nucleosides (Nucleosides and Nucleotides. LXXXI)," Chem. Pharm. Bull., 36(3):945-953 (1988).	_
			_
Fyaminer	Ĭ		_

KAWANA, M., et al., "The deoxygenation of tosylated adenosine derivatives with Grignard

LAVAIRE, S., et al., "3'-Deoxy-3'-C-trifluoromethyl nucleosides: Synthesis and antiviral

LEYSSEN, P. et al., "Perspectives for the treatment of infections with Flaviviridae," Clinical

MARTIN, X., et al., "Intramolecular hydrogen bonding in primary hydroxyl of thymine 1-(1-deoxy-β-

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

branched at the anomeric position," J. Org. Chem., 60(3):656-662 (1995). JOHNSON, C.R., et al, "3'-C-Trifluoromethyl ribonucleosides," Nucleosides & Nucleotides,

evaluation," Nucleosides & Nucleotides, 17(12):2267-2280 (1998).

Microbiology Reviews (Washington, D.C.), 13(1):67-82 (January 2000).

D-psicofuranosyl) nucleoside," Tetrahedron, 50(22):6689-6694 (1994).

reagents," Nucleic Acids Symp. Ser., 17:37-40 (1986).

Borden Hort Statemetal: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the neeth of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patest and Tindemark Office, Weshington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO A. SENDATE COMMISSION CONTROL TO THIS ADDRESS. SEND TO A. SENDATE COMMISSION CONTROL TO THIS ADDRESS. SEND TO A. SENDATE COMMISSION CONTROL TO THIS ADDRESS. SEND TO A. SENDATE COMMISSION CONTROL TO THIS ADDRESS. SEND TO A. SENDATE COMMISSION CONTROL TO THIS ADDRESS. SEND TO A. SENDATE COMMISSION CONTROL TO THE SENDATE CONTROL T

¹ Unique citation designation number: ² See standard Kinds of U.S. Patent Documents. ² Enter Office that issued the document, by the two-letter code (WEPO Standard ST.3). ⁴ For hypenese pants documents, the indication of the year of the reign of the Emperes must procede the serial number of the patent document. ³ Kind closures by the appropriate symbols to includent on the document much relification of the Standard ST.3 in the serial number of the patent document. ³ Kind closures by the appropriate symbols to includent on the document much relification in the serial number of the serial number of the document much religion. ⁴ Application is not the serial number in the patent of the serial number of

Approved far use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMUNICACE

	Under the Paperwo	K Acquiction	Act of 1995, no pers	ons are required to respond in a collection	on of information unless it contains a valid OMB control number.		
Substitute	for form 1449A/PTO			Complete if Known			
				Application Number	10/602,694		
	DRMATION I			Filing Date	June 20, 2003		
STA	STATEMENT BY APPLICANT			First Named Inventor	Sommadossi et al.		
				Group Art Unit	1614		
	(use as many sheets as necessary)			Examiner Name	Unassigned		
Sheet	5	of	6	Attorney Docket Number 06171.105073 IDX 1006 CON1			

3425635 1 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published No. EA MATSUDA, A., et al., "Nucleosides and Nucleotides. 94. Radical deoxygenation of tert-alcohols in 1-(2-C-alkylpentofuranosyl)pyrimidines: Synthesis of (2'5)-2'-deoxy-2'-C-methylcytidine, an antileukemic nucleoside, "J. Med. Chem., 34:234-239 (1991). FR MATSUDA, A., et al., "Nucleosides and Nucleotides. 104. Radical and palladium-catalyzed deoxygenation of the allylic alcohol systems in the sugar moiety of pyrimidine nucleosides," Nucleosides & Nucleotides, 11(2/4):197-226 (1992). EC MIKHAILOV, S.N., et al., "Synthesis and properties of 3'C-methylnucleosides and their phosphoric esters," Carbohydrate Research, 124:75-96 (1983). MIKHAILOV, S.N., et al., "Substrate properties of C'-methylnucleoside and C'-methyl-2'deoxynucleoside 5'-triphosphates in RNA and DNA synthesis reactions catalysed by RNA and DNA polymerases," Nucleosides & Nucleotides, 10(1-3):339-343 (1991). MIKHAILOV, S.N., et al, "Hydrolysis of 2'- and 3'-C-methyluridine 2'c3'-cyclic monophosphates FE and interconversion and dephosphorylation of the resulting 2'- and 3'-monophosphates: Comparison with the reactions of uridine monophosphates," J. Org. Chem., 57 (15):4122-4126 (1992). NUTT, R.F., et al., "Branched-chain sugar nucleosides. III. 3'-C-methyladenine", J. Org. Chem., 33:1789-1795 (1968). EG OIVANEN, M., et al, "Additional evidence for the exceptional mechanism of the acid-catalyzed hydrolysis of 4-oxopyrimidine nucleosides: Hydrolysis of 1-(1-alkoxyalkyl)uracils, seconucleosides, 3'-C-alkyl nucleosides and nucleoside 3',5'-cyclic monophosphates," J. Chem. Soc. Perkin Trans. 2, 1994:309-314 (1994). EH ONG, S.P., et al, "Synthesis of 3'-C-methyladenosine and 3'-C-methyluridine diphosphates and their interaction with the ribonucleoside diphosphate reductase from Corynebacterium nephridii." Biochemistry, 31(45):11210-11215 (1992). Oral Session V, Hepatitis C Virus, Flaviviridae; 16th International Conference on Antiviral Research (April 27, 2003, Savannah, Ga.) p A75-77. PAN-ZHOU, X-R, et al., "Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells," Antimicrob. Agents Chemother., 44:496-503 (2000). EK ROSENTHAL, A., et al., "Branched-chain sugar nucleosides. Synthesis of 3'-C-ethyl (and 3'-Cbutyl)uridine Carbohydrate Research, 79:235-242 (1980). SAMANO, V., et al., "Synthesis and radical-induced ring-opening reactions of 2'-deoxyadenosine-2'spirocyclopropane and its uridine analogue. Mechanistic probe for ribonucleotide reductases," J. Am. Chem. Soc., 114:4007-4008 (1992).

Examiner Signature	Date Considered	3/	31/	05
		_	_	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{**}Listing exclusion designation number: **See transhed Kinds of U.S. Patent Documents. **Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Apparent patents documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **Lind of comment by the appropriate symbols as indicated on the document must off by Standard ST.10 (Forsible. **Application is to plate a check mark here it English language Translation is number.)

**The object of the comment of the Standard ST.10 (Forsible. **Application is to plate a check mark here it English language Translation is number.)

Burden Hore Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to exposite this flow making the sense to the Chief Information Officer. U. S. Patters and Trademark Office, Weshington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENTO TO. Assistant Commissione for Partiess, Weshington, C 20231.

Approved for use through 07/31/2006, OMB 0651-003 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	Under the Paperwo	rk Reduction /	Let of 1995, no perso	ons are required to respond to a collectic	on of information unless it contains a valid OMB control oumber.		
Substitu	te for form 1449A/PTO			Complete if Known			
1				Application Number	10/602,694		
	ORMATION D			Filing Date	June 20, 2003		
STA	TEMENT BY	APPLI	CANT	First Named Inventor	Sommadossi et al.		
ı				Group Art Unit	1614		
L	(use as many sheets	as necessary	n	Examiner Name	Unassigned		
Sheet	6	of	6	Attorney Docket Number	06171.105073 IDX 1006 CON1		

3425635 1 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, nitials * No. journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. SAMANO, V., et al., "Nucleic acid related compounds. 77. 2',3'-Didehydro-2',3'-dideoxy-2'(and 3')-methylnucleosides via [3,3]-sigmatropic rearrangements of 2'(and 3')-methylene-3'(and 2')-Othiocarbonyl derivatives and radical reduction of a 2'-chloro-3'-methylene analogue," Can. J. Chem. 71:186-191 (1993). SCHMIT, C., et al, "The effects of 2'- and 3'-alkyl substituents on oligonucleotide hybridization and stability," Biorganic & Medicinal Chemistry Letters, 4(16):1969-1974 (1994). ["Altmann"] SERAFINOWSKI, P.J., et al., "New method for the preparation of some 2'- and 3'-trifluoromethyl-2',3'-dideoxyuridine derivatives," Tetrahedron (Elsevier Science Publishers), 56(2):333-339 (1999). SHARMA, P.K., et al., "Synthesis of 3'-trifluoromethyl nucleosides as potential antiviral agents," Nucleosides, Nucleotides and Nucleic Acids, 19(4):757-774 (2000). SOMMADOSSI J-P, et al., "Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2',3'dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells" Biochemical Pharmacology. 44:1921-1925 (1992). SOMMADOSSI J-P, et al., "Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro" Antimicrobial Agents and Chemotherapy, 31:452-454 (1987). TRITSCH, D., et al., "3'-β-ethynyl and 2'-deoxy-3'-β-ethynyl adenosines: First 3'-β-branched FG adenosines substrates of adenosine deaminase," Bioorganic & Medicinal Chemistry Letters, 10:139-TUNITSKAYA, V.L., et al., "Substrate properties of C'-methyl UTP derivatives in T7 RNA polymerase reactions. Evidence for N-type NTP conformation," FEBS Letters, 400:263-266 (1997). USUI, H., et al., "Synthesis of 2'-deoxy-8,2'-ethanoadenosine and 3'-deoxy-8,3'-ethanoadenosine (Nucleosides and Nucleotides. LXIV)," Chem. Pharm. Bull., 34(1):15-23 (1986). FI WALCZAK, K., et al., "Synthesis of 1-(3-alkyl-2,3-dideoxy-D-pentofuranosyl)uracils with potential anti-HIV activity," Acta Chemica Scand., 45:930-934 (1991). WALTON, E., et al., "Branched-chain sugar nucleosides. V. Synthesis and antiviral properties of several branched-chain sugar nucleotides," J. Med. Chem., 12:306-309 (1969). FL WOLFE, M.S., et al., "A concise synthesis of 2'-C-methylribonucleosides," Tetrahedron Letters. 36(42):7611-7614 (1995). WU, J.-C., et al., "A new stereospecific synthesis of [3.1.0] bicyclic cyclopropano analog of 2'.3'-FΜ dideoxyuridine. Tetrahedron, 46(7):2587-2592 (1990).

Examiner Signature	Date Considered	3/31/05
		1, 1, 1

^{*}EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{**!} Unique critation designation number: **See standard Kinds of U.S. Prants Documents. **Enter Office that issued the document, by the two-letner code (WIPO Standard ST.3). **For Apparence paramet documents, the ladication of the year of the relign of the Emperor must procede the serial number of the parent document. **Rised of document by the appropriate symbols as indication of the document much of the Post Standard ST.1 of proposite. **Application is to parket active transfer here it English Reposite Practication is transfer. **The Post Standard ST.1 of proposite. **Application is to parket active transfer here it English Reposite Practication is transfer. **The Post Standard ST.1 of proposite. **Application is to parket active transfer here it English Reposite Practication is transfer. **The Post Standard ST.1 of proposite. **The Post Standard ST.1 of proposi

Brotes Now Seasones: This form is estimated to take 2.0 hours to complete. Time will vary deponding upon the needs of the individual case. Any comments on the amount of time you are required to complete the form should be sent to the Chief Information Officer. U. S. Petrat and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TOR Assistant Commissione for Persex. Washington, C 20231.